0.1400
0.0000
(0.00%)
As of April 10 at 11:02:24 AM EDT. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
1,489.7400
1,182.6320
1,125.8130
1,481.7670
1,193.3820
Cost of Revenue
429.7830
370.9890
346.3040
363.1530
326.5080
Gross Profit
1,059.9570
811.6430
779.5090
1,118.6140
866.8740
Operating Expense
1,513.0250
1,191.3140
919.9580
850.6620
767.5570
Operating Income
-453.0680
-379.6710
-140.4490
267.9520
99.3170
Net Non Operating Interest Income Expense
3.9560
12.1990
3.9380
13.1830
-3
Other Income Expense
--
209.8900
--
85.9950
10
Pretax Income
-234.8100
-157.5820
-136.5110
367.1300
106.3170
Net Income Common Stockholders
-268.2490
-157.5820
-136.5110
367.1300
106.3170
Diluted NI Available to Com Stockholders
-268.2490
-157.5820
-136.5110
367.1300
106.3170
Basic EPS
-0.01
-0.00
-0.00
0.01
0.00
Diluted EPS
-0.01
-0.00
-0.00
0.01
0.00
Basic Average Shares
49,516.6720
38,914.1870
38,909.6120
38,818.8590
36,937.0030
Diluted Average Shares
49,516.6720
39,124.2910
39,462.4500
39,292.8040
37,754.4020
Total Expenses
1,942.8080
1,562.3030
1,266.2620
1,213.8150
1,094.0650
Net Income from Continuing & Discontinued Operation
-268.2490
-157.5820
-136.5110
367.1300
106.3170
Normalized Income
-482.5510
-367.4720
-136.5110
303.9237
98.9670
Interest Income
3.9560
12.7560
8.9540
17.5660
--
Interest Expense
--
0.5570
5.0160
4.3830
3
Net Interest Income
3.9560
12.1990
3.9380
13.1830
-3
EBIT
-242.1390
-157.0250
-131.4950
371.5130
109.3170
EBITDA
-179.5550
-78.7610
-17.3300
442.4080
127.2540
Reconciled Cost of Revenue
429.7830
370.9890
346.3040
363.1530
326.5080
Reconciled Depreciation
62.5840
78.2640
114.1650
70.8950
17.9370
Net Income from Continuing Operation Net Minority Interest
-268.2490
-157.5820
-136.5110
367.1300
106.3170
Total Unusual Items Excluding Goodwill
214.3020
209.8900
--
85.9950
10
Total Unusual Items
214.3020
209.8900
--
85.9950
10
Normalized EBITDA
-393.8570
-288.6510
-17.3300
356.4130
117.2540
Tax Rate for Calcs
--
--
--
0.0003
0.0003
Tax Effect of Unusual Items
--
--
--
22.7887
2.6500
12/31/2020 - 2/13/2008
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
IMC.AX Immuron Limited
0.0670
+1.52%
CVALF Covalon Technologies Ltd.
1.6300
-2.40%
KNE.V Kane Biotech Inc.
0.1000
0.00%
GLOW.CN Glow Lifetech Corp.
0.0650
0.00%
QPT.V Quest PharmaTech Inc.
0.0500
-9.09%
IMRN Immuron Limited
1.7900
+9.64%
MBX.TO Microbix Biosystems Inc.
0.3450
-1.43%
HEM.V Hemostemix Inc.
0.0950
+5.56%
MIR.V MedMira Inc.
0.0950
+18.75%
RYTM Rhythm Pharmaceuticals, Inc.
59.34
+2.60%